ENTERA BIO LTD. Other Finance Income Cost
ENTERA BIO LTD. (ENTX) reported Other Finance Income Cost of -$37.00 thousand for the 3-month period ending 2021-06-30, per its 6-K filed 2021-08-16.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:OtherFinanceIncomeCost · last filed 2021-08-16
- ENTERA BIO LTD. other finance income cost for the quarter ending 2021-06-30 was -$37.00K.
- ENTERA BIO LTD. other finance income cost for the quarter ending 2020-06-30 was -$29.00K.
- ENTERA BIO LTD. other finance income cost for the quarter ending 2019-06-30 was -$19.00K.
| Period end | Other Finance Income Cost 3 month | Other Finance Income Cost 6 month | Other Finance Income Cost 12 month |
|---|---|---|---|
| 2021-06-30 | -$37.00K 6-K · filed 2021-08-16 | -$25.00K 6-K · filed 2021-08-16 | |
| 2020-12-31 | -$67.00K 20-F · filed 2021-03-18 | ||
| 2020-06-30 | -$29.00K 6-K · filed 2021-08-16 | -$4.00K 6-K · filed 2021-08-16 | |
| 2019-12-31 | -$84.00K 20-F · filed 2021-03-18 | ||
| 2019-06-30 | -$19.00K 6-K · filed 2020-08-20 | -$35.00K 6-K · filed 2020-08-20 | |
| 2018-12-31 | $34.00K 20-F · filed 2021-03-18 | ||
| 2017-12-31 | -$105.00K 20-F · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |